Donanemab
Modify Date: 2024-01-03 08:45:51
Donanemab structure
|
Common Name | Donanemab | ||
|---|---|---|---|---|
| CAS Number | 1931944-80-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of DonanemabDonanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research[1][2]. |
| Name | Donanemab |
|---|
| Description | Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Donanemab 是一种针对 N 末端焦谷氨酸 Aβ 表位的人源化 IgG1 抗体，该表位仅存在于已建立的斑块中。Donanemab 对该表位具有特异性，并且未显示与其他 Aβ 种类、神经递质或其受体的脱靶结合[2]。 |
| References |
| No Any Chemical & Physical Properties |